Crossprotection Induced by Virus-Like Particles Containing Influenza Dual-Hemagglutinin and M2 Ectodomain

References

• Estrada LD , Schultz-CherryS. Development of a universal influenza vaccine. J. Immunol.202(2), 392–398 (2019).
   PubMed Web of Science ®Google Scholar
• Wang WC , SayedahmedEE, SambharaS, MittalSK. Progress towards the development of a universal influenza vaccine. Viruses14(8), 1684–1705 (2022).
   PubMed Web of Science ®Google Scholar
• Merced-Morales A , DalyP, AbdElal AIet al. Influenza activity and composition of the 2022–23 influenza vaccine – United States, 2021–22 season. MMWR Morb. Mortal. Wkly Rep.71(29), 913–919 (2022).
   PubMed Web of Science ®Google Scholar
• Lu P , BridgesCB, EulerGL, SingletonJA. Influenza vaccination of recommended adult populations, US, 1989–2005. Vaccine26(14), 1786–1793 (2008).
   PubMed Web of Science ®Google Scholar
• De Jong JC , BeyerWE, PalacheAM, RimmelzwaanGF, OsterhausAD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol.61(1), 94–99 (2000).
   PubMed Web of Science ®Google Scholar
• Nachbagauer R , PaleseP. Is a universal influenza virus vaccine possible?Annu. Rev. Med.71, 315–327 (2020).
   PubMed Web of Science ®Google Scholar
• Chu KB , QuanFS. Virus-like particle vaccines against respiratory viruses and protozoan parasites. Curr. Top. Microbiol. Immunol.433, 77–106 (2021).
   PubMed Web of Science ®Google Scholar
• Inn KS , LeeGJ, QuanFS. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol. Invest.43(3), 236–254 (2014).
   PubMed Web of Science ®Google Scholar
• Galarza JM , LathamT, CupoA. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol.18(2), 365–372 (2005).
   PubMed Web of Science ®Google Scholar
• Quan FS , VunnavaA, CompansRW, KangSM. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLOS ONE5(2), e9161 (2010).
   PubMed Web of Science ®Google Scholar
• Rezaei F , MirshafieyA, ShahmahmoodiS, ShojaZ, GhavamiN, Mokhtari-AzadT. Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses. Iran. Red Crescent Med. J.15(1), 75–82 (2013).
   PubMed Web of Science ®Google Scholar
• Quan FS , SteinhauerD, HuangC, RossTM, CompansRW, KangSM. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine26(26), 3352–3361 (2008).
   PubMed Web of Science ®Google Scholar
• Quan FS , CompansRW, NguyenHH, KangSM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol.82(3), 1350–1359 (2008).
   PubMed Web of Science ®Google Scholar
• Kang SM , SongJM, QuanFS, CompansRW. Influenza vaccines based on virus-like particles. Virus Res.143(2), 140–146 (2009).
   PubMed Web of Science ®Google Scholar
• Lee YN , KimMC, LeeYT, KimYJ, KangSM. Mechanisms of cross-protection by influenza virus M2-based vaccines. Immune Netw.15(5), 213–221 (2015).
   PubMed Web of Science ®Google Scholar
• Kim MC , SongJM, EunjuEet al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther.21(2), 485–492 (2013).
   PubMed Web of Science ®Google Scholar
• Kim KH , LiZ, BhatnagarNet al. Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle. PLOS Pathog.18(8), e1010755 (2022).
   PubMedGoogle Scholar
• Kang HJ , ChuKB, LeeDHet al. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLOS ONE14(6), e0216871 (2019).
   PubMed Web of Science ®Google Scholar
• Kang SM , YooDG, LipatovASet al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLOS ONE4(3), e4667 (2009).
   PubMed Web of Science ®Google Scholar
• Kang HJ , ChuKB, YoonKW, EomGD, MaoJ, QuanFS. Cross-protection induced by virus-like particles derived from the influenza B virus. Biomedicines10(7), 1618–1631 (2022).
   PubMed Web of Science ®Google Scholar
• Chu KB , KangHJ, YoonKWet al. Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 S glycoprotein, S1, or S2 domains. Vaccines (Basel)9(8), 920–935 (2021).
   PubMed Web of Science ®Google Scholar
• Quan FS , HuangC, CompansRW, KangSM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol.81(7), 3514–3524 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson S , CrottaS, MccabeTM, WackA. Pathogenic potential of interferon αβ in acute influenza infection. Nat. Commun.5(1), 3864 (2014).
   PubMedGoogle Scholar
• Yu Y , XuN, ChengQet al. IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Rep.37(12), 110126–110143 (2021).
   PubMed Web of Science ®Google Scholar
• Mao J , EomGD, YoonKW, KangHJ, ChuKB, QuanFS. Sublingual vaccination with live influenza virus induces better protection than oral immunization in mice. Life (Basel)12(7), 975–987 (2022).
   PubMed Web of Science ®Google Scholar
• Basak S , KangHJ, LeeSH, ChuKB, MoonEK, QuanFS. Influenza vaccine efficacy induced by orally administered recombinant baculoviruses. PLOS ONE15(5), e0233520 (2020).
   PubMed Web of Science ®Google Scholar
• Dong C , WangY, ZhuWet al. Polycationic HA/CpG nanoparticles induce cross-protective influenza immunity in mice. ACS Appl. Mater. Interfaces14(5), 6331–6342 (2022).
   PubMed Web of Science ®Google Scholar
• Abreu RB , ClutterEF, AttariS, SauttoGA, RossTM. IgA responses following recurrent influenza virus vaccination. Front. Immunol.11, 902 (2020).
   PubMed Web of Science ®Google Scholar
• Trombetta CM , MarchiS, ManiniI, LazzeriG, MontomoliE. Challenges in the development of egg-independent vaccines for influenza. Expert Rev. Vaccines18(7), 737–750 (2019).
   PubMed Web of Science ®Google Scholar
• Trombetta CM , MarchiS, MontomoliE. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing. Expert Rev. Vaccines21(9), 1233–1242 (2022).
   PubMed Web of Science ®Google Scholar
• Quan FS , LeeYT, KimKH, KimMC, KangSM. Progress in developing virus-like particle influenza vaccines. Expert Rev. Vaccines15(10), 1281–1293 (2016).
   PubMed Web of Science ®Google Scholar
• Laursen NS , WilsonIA. Broadly neutralizing antibodies against influenza viruses. Antiviral Res.98(3), 476–483 (2013).
   PubMed Web of Science ®Google Scholar
• Dong W , BhideY, SiccaFet al. Cross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccines. Front. Immunol.9, 2312 (2018).
   PubMed Web of Science ®Google Scholar
• Wang L , LiuS-Y, ChenH-Wet al. Generation of a live attenuated influenza vaccine that elicits broad protection in mice and ferrets. Cell Host Microbe21(3), 334–343 (2017).
   PubMed Web of Science ®Google Scholar
• Herold S , BeckerC, RidgeKM, BudingerGR. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur. Respir. J.45(5), 1463–1478 (2015).
   PubMed Web of Science ®Google Scholar
• Renegar KB , SmallPAJr , BoykinsLG, WrightPF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol.173(3), 1978–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Ernst WA , KimHJ, TumpeyTMet al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine24(24), 5158–5168 (2006).
   PubMed Web of Science ®Google Scholar
• Keshavarz M , NamdariH, ArjeiniYet al. Induction of protective immune response to intranasal administration of influenza virus-like particles in a mouse model. J. Cell. Physiol.16643–16652(.2019).
   PubMed Web of Science ®Google Scholar
• Tamura S , AinaiA, SuzukiT, KurataT, HasegawaH. Intranasal inactivated influenza vaccines: a reasonable approach to improve the efficacy of influenza vaccine?Jpn J. Infect. Dis.69(3), 165–179 (2016).
   PubMed Web of Science ®Google Scholar
• Perrone LA , AhmadA, VeguillaVet al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol.83(11), 5726–5734 (2009).
   PubMed Web of Science ®Google Scholar
• Ainai A , SuzukiT, TamuraSI, HasegawaH. Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate. Viral Immunol.30(6), 451–462 (2017).
   PubMed Web of Science ®Google Scholar
• Wei CJ , CrankMC, ShiverJ, GrahamBS, MascolaJR, NabelGJ. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov.19(4), 239–252 (2020).
   PubMed Web of Science ®Google Scholar
• Low JG , LeeLS, OoiEEet al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized phase I clinical trial in healthy Asian volunteers. Vaccine32(39), 5041–5048 (2014).
   PubMed Web of Science ®Google Scholar
• Valero-Pacheco N , Pérez-ToledoM, Villasís-KeeverMet al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine. PLOS ONE11(2), e0150146 (2016).
   PubMed Web of Science ®Google Scholar
• Nachbagauer R , KrammerF. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect.23(4), 222–228 (2017).
   PubMed Web of Science ®Google Scholar
• Jansen JM , GerlachT, ElbaheshH, RimmelzwaanGF, SalettiG. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol.119, 44–52 (2019).
   PubMed Web of Science ®Google Scholar
• Koutsakos M , IllingPT, NguyenTHOet al. Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses. Nat. Immunol.20(5), 613–625 (2019).
   PubMed Web of Science ®Google Scholar
• La Gruta NL , TurnerSJ. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol.35(8), 396–402 (2014).
   PubMed Web of Science ®Google Scholar